UniQure had planned to seek accelerated approval for AMT-130 early 2026, but then said its plans were stalled after ...
Topline data were announced from two phase 3 trials evaluating amlitelimab for the treatment of moderate to severe atopic dermatitis.
More than one-third of patients with cutaneous chronic graft-versus-host disease had a perception of treatment response that ...
A daily preventive pill can be invaluable for people at risk for HIV. But some doctors don't know much about prescribing them and billing headaches are common. Here’s how to overcome those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results